123 related articles for article (PubMed ID: 25667043)
1. Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Montariello D; Troiano A; Di Girolamo D; Beneke S; Calabrò V; Quesada P
Biochem Pharmacol; 2015 Apr; 94(3):212-9. PubMed ID: 25667043
[TBL] [Abstract][Full Text] [Related]
2. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Cimmino G; Pepe S; Laus G; Chianese M; Prece D; Penitente R; Quesada P
Pharmacol Res; 2007 Jan; 55(1):49-56. PubMed ID: 17127074
[TBL] [Abstract][Full Text] [Related]
5. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
6. Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Sabisz M; Wesierska-Gadek J; Skladanowski A
Biochem Pharmacol; 2010 May; 79(10):1387-97. PubMed ID: 20067769
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
[TBL] [Abstract][Full Text] [Related]
8. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells.
Cui Q; Yu JH; Wu JN; Tashiro S; Onodera S; Minami M; Ikejima T
Acta Pharmacol Sin; 2007 Jul; 28(7):1057-66. PubMed ID: 17588343
[TBL] [Abstract][Full Text] [Related]
9. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase.
Vaziri H; West MD; Allsopp RC; Davison TS; Wu YS; Arrowsmith CH; Poirier GG; Benchimol S
EMBO J; 1997 Oct; 16(19):6018-33. PubMed ID: 9312059
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Nguyen D; Zajac-Kaye M; Rubinstein L; Voeller D; Tomaszewski JE; Kummar S; Chen AP; Pommier Y; Doroshow JH; Yang SX
Cell Cycle; 2011 Dec; 10(23):4074-82. PubMed ID: 22101337
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-RIBOSE) polymerase-1 (Parp-1) antagonizes topoisomerase I-dependent recombination stimulation by P53.
Baumann C; Boehden GS; Bürkle A; Wiesmüller L
Nucleic Acids Res; 2006; 34(3):1036-49. PubMed ID: 16473854
[TBL] [Abstract][Full Text] [Related]
12. Note to readers.
Enna SJ
Biochem Pharmacol; 2016 Apr; 105():101. PubMed ID: 26891918
[No Abstract] [Full Text] [Related]
13. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.
Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C
Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390
[TBL] [Abstract][Full Text] [Related]
14. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
15. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Huang SH; Xiong M; Chen XP; Xiao ZY; Zhao YF; Huang ZY
Oncol Rep; 2008 Sep; 20(3):567-72. PubMed ID: 18695907
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment.
Kumari SR; Mendoza-Alvarez H; Alvarez-Gonzalez R
Cancer Res; 1998 Nov; 58(22):5075-8. PubMed ID: 9823314
[TBL] [Abstract][Full Text] [Related]
17. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase.
Agarwal ML; Agarwal A; Taylor WR; Wang ZQ; Wagner EF; Stark GR
Oncogene; 1997 Aug; 15(9):1035-41. PubMed ID: 9285557
[TBL] [Abstract][Full Text] [Related]
18. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity.
Preet R; Mohapatra P; Mohanty S; Sahu SK; Choudhuri T; Wyatt MD; Kundu CN
Int J Cancer; 2012 Apr; 130(7):1660-70. PubMed ID: 21544805
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Whitacre CM; Berger NA
Cancer Res; 1997 Jun; 57(11):2157-63. PubMed ID: 9187115
[TBL] [Abstract][Full Text] [Related]
20. The monofunctional alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine triggers apoptosis through p53-dependent and -independent pathways.
Kim WJ; Beardsley DI; Adamson AW; Brown KD
Toxicol Appl Pharmacol; 2005 Jan; 202(1):84-98. PubMed ID: 15589979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
